marketcaparena
Search

    SCTX

    Scribe Therapeutics, Inc.

    Company overview

    Market capitalization
    $412.14M
    Employees
    —
    Latest publication
    2026-09-29

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Total Revenue1,918,000USD
    Research Development8,823,000USD
    Selling General Administrative2,490,000USD
    General And Administrative Expenses2,490,000USD
    Total Operating Expenses11,313,000USD
    Operating Income-9,395,000USD
    Total Other Income Expense Net3,130,000USD
    Interest Expense276,000USD
    Income Before Tax-6,265,000USD
    Income Tax Expense212,000USD
    Net Income-6,477,000USD
    SourceDisclosureDeterministicFinal

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Total Assets57,927,000USD
    Cash And Equivalents35,586,000USD
    Cash And Short Term Investments43,009,000USD
    Short Term Investments7,423,000USD
    Total Current Assets45,105,000USD
    Other Current Assets989,000USD
    Other Non Current Assets3,610,000USD
    Total Liabilities102,417,000USD
    Total Current Liabilities78,697,000USD
    Other Current Liabilities2,414,000USD
    Other Non Current Liabilities7,920,000USD
    Total Stockholder Equity-164,846,000USD
    Total Equity Including Noncontrolling Interest-44,490,000USD
    Deferred Revenue27,475,000USD
    Net Receivables1,107,000USD
    Property Plant Equipment Net8,537,000USD
    Accounts Payable2,771,000USD
    Short Term Debt1,369,000USD
    Common Stock14,000USD
    Retained Earnings-181,531,000USD
    Accumulated Other Comprehensive Income-2,000USD
    SourceDisclosureDeterministicFinal

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation1,277,000USD
    Stock Based Compensation2,197,000USD
    Other Non Cash Items-1,585,000USD
    Change To Account Receivables5,985,000USD
    Change To Liabilities-3,216,000USD
    Change In Working Capital4,216,000USD
    Operating Cash Flow-12,892,000USD
    Capital Expenditures-27,000USD
    Unclassified Investing Cash Flow37,497,000USD
    Investing Cash Flow37,470,000USD
    Financing Cash Flow-1,788,000USD
    Change In Cash22,790,000USD
    End Cash Flow36,261,000USD
    SourceDisclosureDeterministicFinal

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    No revenue breakdown is currently published for this company.

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.